NCE-1 Intelligence & Market Opportunity

Rytelo

Imetelstat

Anticancer

Intravenous Powder

Rytelo is a prescription treatment for adults with low-to-intermediate-1 risk myelodysplastic syndromes (MDS) who have anemia and need frequent blood transfusions, and who haven’t responded to or can’t take erythropoiesis-stimulating agents (ESAs).

Approval Date

06-Jun-24

NCE-1 Date

06-Jun-28

NCE Date

06-Jun-29

Commercial snapshot

Market performance & projections

Revenue ($M)

184

CAGR (%)

0.4128

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

243

2027

363

2028

557

2029

733

2030

913

2031

1069

2032

1212

Molecule profile

Details & specifications

Molecule

Imetelstat

Innovator

GERON CORP

Dosage Form

Intravenous Powder

Strength

EQ 47 mg base/vial & EQ 188 mg base/vial

Therapeutic Category

Anticancer

Usage

To treat low- to intermediate-1 risk myelodysplastic syndromes

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.